证券代码：688115 证券简称：思林杰 公告编号：2025-039 广州思林杰科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 广州思林杰科技股份有限公司（以下简称"公司"）第二届监事会第十六次 会议于 2025 年 7 月 30 日在公司会议室以现场方式召开，会议通知及会议材料 于 2025 年 7 月 28 日以电子邮件方式送达全体监事。会议应参加监事 3 人，实 际参加监事 3 人，董事会秘书列席本次会议。全体监事已在充分阅读并理解公 司本次第二届监事会第十六次会议议案的全部内容基础上，同意公司本次第二 届监事会第十六次会议豁免提前三天通知，并确定对本次第二届监事会第十六 次会议的通知、召集和召开无异议。会议的召集和召开符合《公司法》和《公 司章程》等有关规定，会议合法、有效。会议由监事会主席吴艳女士主持，与 会监事以记名投票方式投票表决，经认真研究审议形成决议如下： 二、监事会会议审议情况 （一）审议通过了《关于修订 <广州思林杰科技股份有限公司发行股份及> 支付现金购买资 ...

证券代码：600933 证券简称：爱柯迪 公告编号：临 2025-081 本次会议由公司监事会主席许晓彤女士主持。 转债代码：110090 转债简称：爱迪转债 爱柯迪股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议基本情况 爱柯迪股份有限公司（以下简称"公司"）第四届监事会第十次会议于 2025 年 7 月 30 日在公司三楼会议室以通讯表决方式召开。公司于 2025 年 7 月 25 日 以电子邮件的方式向各位监事发出本次会议的通知、会议议案及相关文件。与会 的各位监事已经知悉与本次会议所议事项相关的必要信息。 本次会议应到会监事 3 人，实际到会监事 3 人。公司董事会秘书列席了本次 会议。 本次会议监事出席人数、召开符合《公司法》等相关法律法规及《公司章程》 的有关规定。 二、议案审议情况 出席监事认真审议了下述议案，并以记名投票表决的方式进行表决： （一）审议通过《关于 <爱柯迪股份有限公司发行股份及支付现金购买资产> 并募集配套资金报告书（草案）（修订稿）>及其摘要的议案》 根据《证券法》《上市 ...

Core Viewpoint - Lidman is planning to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which is expected to constitute a major asset restructuring [1][4]. Group 1: Acquisition Details - The acquisition will be funded through self-owned funds and bank merger loans, with Lidman not holding any shares in the target company prior to the transaction [4]. - Upon completion of the acquisition, Lidman will gain control of the target company, which will become a subsidiary [4]. - The investment framework agreement signed with the target company and its shareholders is only a preliminary agreement, with specific terms to be defined in formal agreements [4]. Group 2: Target Company Overview - The target company operates in the biopharmaceutical manufacturing industry, focusing on in vitro diagnostic reagents and human vaccines [4]. - Its main products include tuberculin purified protein derivative, bacillus Calmette-Guérin purified protein derivative, and specific cell immune response test kits for tuberculosis screening, diagnosis, treatment, and innovative vaccine development [4]. Group 3: Financial Performance - In 2024, Lidman reported a revenue of approximately 370 million yuan, a year-on-year decrease of 19.79%, with a net profit of -75.1 million yuan [6]. - The in vitro diagnostic reagent business remains the primary revenue source, generating about 297 million yuan, down 22.06%, accounting for 80.29% of total revenue [6]. - The first quarter of 2025 saw revenues of approximately 78.9 million yuan, a year-on-year decline of 16.61%, with a net profit of -1.25 million yuan [6]. Group 4: Market Position - As of July 30, Lidman's stock price was 5.87 yuan per share, with a market capitalization of 3.2 billion yuan [7].

中盐内蒙古化工股份有限公司于2025年7月24日披露重大资产重组草案，拟同意参股公司中盐（内蒙 古）碱业有限公司向股东中石油太湖（北京）投资有限公司定向减资，完成后中盐碱业将成为其全资子 公司。上海证券交易所于7月30日就此发布问询函，针对多项关键问题要求公司进一步说明和补充披 露。 交易目的存疑 中盐内蒙古化工主营 盐化工 业务，目前生产 纯碱 采用合成法，而天然碱法成本优势明显，公司计划通 过此次交易控股标的公司并投资500万吨/年纯碱产能的天然碱项目。但2022年至2025年1 - 6月纯碱价格 持续下降，上交所要求公司： 2.后续项目建设的资金投入计划与筹措安排，结合公司现有财务状况、融资能力及未来现金流预测，分 析对公司偿债、营运、短期及长期盈利能力的影响，并充分提示风险。同时请独立财务顾问和会计师发 表意见。 采矿权估值待明晰 公司聘请估值机构对天然碱采矿权采用收益法估值，金额为70.17亿元。2025年1 - 6月纯碱均价1,369.04 元/吨，收益法预测初期价格1,250元/吨，5年后涨至1,321元/吨，且草案提示新增产能可能影响价格。上 交所要求公司： 1.结合市场供需、行业周期、竞争环 ...

Core Viewpoint - The company is undergoing a significant asset restructuring involving its subsidiary, aiming to enhance its production capabilities in the soda ash sector, particularly through the adoption of natural soda production methods, which are expected to be more cost-effective than synthetic methods [3]. Group 1: Financial Performance - For the year 2024, the company's revenue composition is as follows: industrial business accounts for 96.83%, while other businesses contribute 3.17% [1]. Group 2: Asset Restructuring - On July 30, 2025, the Shanghai Stock Exchange issued an inquiry regarding the company's major asset restructuring draft, which was disclosed on July 24, 2025 [3]. - The restructuring involves a capital reduction of the subsidiary, Zhongyan (Inner Mongolia) Soda Industry Co., Ltd., which will become a wholly-owned subsidiary of the company after the reduction [3]. - The company plans to invest in a natural soda project, with an expected production capacity of 5 million tons per year [3]. Group 3: Market Conditions - From 2022 to June 2025, the price of soda ash has been on a continuous decline, raising concerns about the market dynamics and the company's pricing strategy [3].

证券日报网讯电投产融（000958）7月30日在互动平台回答投资者提问时表示，电投产融当下正推进重 大资产重组。截至目前，公司业务架构未发生重大变化，且重大资产重组事项尚未完成。在重组交割 前，所有经营主体的业绩均依法纳入合并报表范围。根据相关监管程序，本次重组项目后续还需获得深 交所审核通过、中国证监会同意注册、取得相关法律法规要求的其他必要批准或核准等环节。交易完成 时间具有不确定性，公司将依法合规推进重组工作，并严格按照相关规定履行信息披露义务。 ...

Core Viewpoint - The company, Saiwei Electronics, has sold the control of its core subsidiary, Silex Microsystems AB, to mitigate risks associated with the increasingly complex international geopolitical environment, receiving approximately 1.783 billion RMB from the transaction [1][2][5]. Financial Performance - In 2024, Silex contributed 71.60% of Saiwei's total revenue, amounting to 863 million RMB [2][5]. - Since its listing over ten years ago, Saiwei has reported a cumulative net profit of 629 million RMB, with a loss of 170 million RMB in 2024 [2]. - The company has raised a total of 3.868 billion RMB through equity financing and distributed only 155 million RMB in cash dividends [3][11]. Transaction Details - The transaction involved the sale of 4.4101 million shares of Silex, representing 45.24% of the company, for a total valuation of 5.25 billion SEK (approximately 3.942 billion RMB) [5]. - Prior to the sale, Silex had distributed dividends of 250 million SEK to Saiwei [5]. Business Operations - Saiwei's primary business includes MEMS chip process development and wafer manufacturing, with significant operations in both Sweden and Beijing [6]. - Following the sale, Silex will remain a subsidiary, but Saiwei will focus on its Beijing operations, which are expected to expand production capacity from 15,000 to 30,000 wafers per month [6]. Management Actions - The actual controller of Saiwei, Yang Yunchun, has reportedly cashed out approximately 2.37 billion RMB through various means, including share reductions [4][13]. - Yang's shareholding has decreased from 45.58% in Q3 2019 to 24.46% by Q1 2025 [14].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600397 证券简称：安源煤业 公告编号：2025-065 安源煤业集团股份有限公司 关于召开重大资产重组投资者说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资者可于2025年7月30日（星期三）至8月5日（星期二）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱aymyjt2025@163.com进行提问。公司将在说明会上对投资者普遍 关注的问题进行回答。 安源煤业集团股份有限公司（以下简称"公司"）于2025年7月25日召开第九届董事会第三次会议，审议 通过了《关于〈安源煤业集团股份有限公司重大资产置换暨关联交易报告书（草案）（修订稿）〉及其 摘要的议案》等议案，具体内容详见公司于2025年7月26日在上海证券交易所网站 （http://www.sse.com.cn）披露的《安源煤业集团股份有限公司重大资产置换暨关联交易报告书（草 案）（修订稿）》及其摘要等相关公告。为了便于广大投资者更全面深入地了 ...

证券代码：600397 证券简称：安源煤业 公告编号：2025-065 安源煤业集团股份有限公司 关于召开重大资产重组投资者说明会的公告 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 8 月 6 日（星期三）10:15-11:15 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 安源煤业集团股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开第 九届董事会第三次会议，审议通过了《关于 <安源煤业集团股份有限公司重大资> 产置换暨关联交易报告书（草案）（修订稿）>及其摘要的议案》等议案，具体 内容详见公司于 2025 年 7 月 26 日在上海证券交易所网站（http://www.sse.com.cn） 披露的《安源煤业集团股份有限公司重大资产置换暨关联交易报告书（草案） （修 订稿）》及其摘要等相关公告。为了便于广大投资者更全面深入地了解本次重大 资产重组相关情况。公司计划于 2025 年 8 月 6 日上午 10:15-11:15 召开重大资产 重组投资者说明会，就投资者关心 ...

Core Viewpoint - Zhongyan Chemical is undergoing a significant asset restructuring involving a capital reduction of its subsidiary, Zhongyan (Inner Mongolia) Soda Industry Co., Ltd., through a directed capital reduction to Taihu Investment, a subsidiary of China National Petroleum Corporation [1] Group 1: Asset Restructuring Details - The company disclosed a draft report on the major asset restructuring related to the capital reduction on July 24, 2025 [1] - The restructuring report has been revised to include additional details on the valuation process of the natural soda mining rights being auctioned by the subsidiary [1] - The revisions involved the addition of a section detailing the valuation process and the removal of redundant content from the original report [1]